Drug interactions
Risankizumab + Upadacitinib
Severity: Major
Risankizumab and Upadacitinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Risankizumab blocks IL-23 and upadacitinib inhibits JAK signaling. They are sometimes considered together in inflammatory bowel disease, but combined immunosuppression may increase infection risk and data on safety are limited.
What this interaction means in plain words
Risankizumab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Risankizumab belongs to Miscellaneous; Upadacitinib belongs to Musculoskeletal.
Why it happens
Additive immunosuppression through IL-23 blockade and JAK inhibition.
What to do
Avoid routine combination; if used, screen for tuberculosis and hepatitis beforehand and monitor for infections.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Risankizumab and Upadacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Upadacitinib
- Abrocitinib + Upadacitinib Contraindicated
- Adenovirus types 4 and 7 live + Upadacitinib Contraindicated
- Baricitinib + Upadacitinib Contraindicated
- Bcg vaccine live + Upadacitinib Contraindicated
- Cyclosporine + Upadacitinib Contraindicated
- Dengue vaccine + Upadacitinib Contraindicated
Other interactions of Risankizumab
Frequently asked questions
Can I take Risankizumab with Upadacitinib?
MediHelp rates the interaction as major. Risankizumab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Risankizumab blocks IL-23 and upadacitinib inhibits JAK signaling. They are sometimes considered together in inflammatory bowel disease, but combined immunosuppression may increase infection risk and data on safety are limited.
How serious is the interaction between Risankizumab and Upadacitinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid routine combination; if used, screen for tuberculosis and hepatitis beforehand and monitor for infections.
What other medicines interact with Upadacitinib?
MediHelp also lists interactions of Upadacitinib with, for example, Abrocitinib, Adenovirus types 4 and 7 live, Baricitinib. The full list is on the Upadacitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
